文献速递糖尿病

β细胞功能障碍识别单抗体阳性个体中1型糖尿病进展高风险者

β-Cell Dysfunction Identifies Individuals With Single Autoantibody Positivity at Increased Risk of Type 1 Diabetes Progression.
PubMed 文献 · Diabetes Care · 2026-09-02

在TrialNet自然史研究中,对1型糖尿病患者的单抗体阳性亲属评估代谢指标与进展风险的关系。结果显示,联合口服葡萄糖耐量试验刺激的血糖和C肽评估β细胞功能障碍,与各年龄段和抗体谱的进展风险均呈强而一致的关联,数据驱动切点可区分极高风险(>50% 2年进展)和低风险(<10% 5年进展)亚组。

要点

  • 单抗体阳性者代谢功能差异大,联合刺激后血糖和C肽可识别进展高风险。
  • 传统风险因素、孤立血糖或C肽、胰岛素抵抗指标的关联因年龄和抗体类型而异。
  • 数据驱动切点可区分2年进展>50%的高风险亚组和5年进展<10%的低风险亚组。

核心结论

  • β细胞功能障碍存在于许多单抗体阳性个体中,并与疾病进展风险增加相关。
  • 结合刺激后β细胞功能指标、年龄和抗体谱可能实现更个性化监测。

研究设计与样本

  • TrialNet Pathway to Prevention自然史研究中,筛查并确认单抗体阳性的1型和2型糖尿病亲属。
  • 采用Cox比例风险模型评估代谢指标与进展时间的关联,随机森林模型估计变量相对重要性。
  • 分析在整体队列中进行,并按年龄(0-8、≥8-16、≥16岁)分层。

主要发现

  • 单抗体阳性个体代谢功能呈现广泛变异。
  • 联合口服葡萄糖耐量试验刺激的血糖和C肽评估β细胞功能障碍,与进展风险呈强而一致的关联,跨越各年龄段和抗体谱。
  • 传统风险因素、孤立血糖或C肽指标、胰岛素抵抗指数的关联因年龄和抗体类型而异。
  • 数据驱动切点识别出小部分极高风险亚组(>50% 2年进展)和大部分低风险组(<10% 5年进展)。

关键数值与推荐

  • 进展定义为出现多抗体阳性或3期1型糖尿病。
  • 联合代谢指标的数据驱动切点可区分>50% 2年进展的高风险亚组和<10% 5年进展的低风险组。

临床怎么用

  • 在单抗体阳性个体中,可结合刺激后β细胞功能指标、年龄和抗体谱进行更个性化监测。
  • 有助于识别最可能从疾病修饰治疗中获益的个体,并界定需要较少密集监测的低风险者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Individuals with single islet autoantibody positivity exhibit a highly variable risk for type 1 diabetes progression. We evaluated whether metabolic measures identify those at higher progression risk. RESEARCH DESIGN AND METHODS: Among first- and second-degree relatives of persons with type 1 diabetes who screened and confirmed positive for a single autoantibody in the TrialNet Pathway to Prevention Natural History study, we used Cox proportional hazards models to assess associations between metabolic measures and time to progression, defined as the development of multiple autoantibody-positive or stage 3 type 1 diabetes. Random forest models were used to estimate the relative importance of each variable. Analyses were conducted in the overall cohort and stratified by age (0-8, ≥8-16, and ≥16 years). RESULTS: Individuals with single autoantibody positivity exhibited wide variation in metabolic function. Measures incorporating both oral glucose tolerance test-stimulated glucose and C-peptide to assess β-cell dysfunction showed strong and consistent associations with progression across age-groups and antibody profiles. Associations for traditional risk factors, isolated glucose or C-peptide measures, or indices of insulin resistance differed by age and autoantibody type. Data-driven cutoffs for combined metabolic measures identified small subsets at very high risk (>50% 2-year progression) and large low-risk groups with <10% 5-year progression. CONCLUSIONS: β-Cell dysfunction is present in many individuals with single autoantibody positivity and is associated with an increased risk of disease progression. Incorporating stimulated measures of β-cell function alongside age and autoantibody profiles may enable more personalized monitoring, help identify persons most likely to benefit from disease-modifying therapies, and delineate lower-risk individuals who require less intensive surveillance.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Sims EK, You L, Ismail H, et al. β-Cell Dysfunction Identifies Individuals With Single Autoantibody Positivity at Increased Risk of Type 1 Diabetes Progression. Diabetes Care. 2026. PMID: 42684379. doi:10.2337/dc26-1111

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。